approved EB-1A
Scientist
Virology · India · 2021-11-23
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.
Framework Evaluation
3 of 3 criteria metScholarly Articles (Met)
The petitioner authored 11 peer-reviewed scientific articles in international journals.
Judging (Met)
The petitioner completed 25 reviews for international scientific journals in her field.
Original Contributions (Met)
The petitioner contributed original research including 1 patent and significant work on antiviral drugs for influenza and COVID-19, supported by 298 citations.
Why This Petition Was Approved
The petition was approved based on the submission of 11 peer-reviewed scientific articles and 1 patent published in international journals. The petitioner demonstrated a significant impact on the field with 298 citations and established her expertise by conducting 25 peer reviews for international scientific journals. Her decade-long research in antiviral drugs and vaccines was deemed of critical value, especially during the coronavirus pandemic.
Evidence
Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Dependent
Judging Experience
Original Contributions
Evidence Submitted
- 11 peer-reviewed scientific articles
- 1 patent published in international journals
- 298 citations
- 25 reviews for international scientific journals
- Over a decade of research in antiviral drugs and vaccines
Similar Cases
Associate Professor
Healthcare · Canada
WeGreened EB-1A approved
40 days 2026-02-19
The case was approved based on 47 peer-reviewed journal articles and 5 abstracts which garnered 1,369 citations, demonstrating significant independent reliance by the field. Additionally, the petitioner completed 20 peer reviews for selective clinical venues, satisfying the judging and scholarly articles criteria for EB-1A.
Assistant Professor
Research and Development · China
WeGreened EB-1A approved
Florida 16 days 2026-02-18
The case was approved based on a publication record of 33 peer-reviewed articles and 25 completed peer reviews. The petitioner demonstrated extraordinary ability through high citation percentiles, with 10 papers ranked among the most highly cited for their years. Evidence of federal agency support and international reliance across 48 countries satisfied the EB-1A criteria.
Scientist
Research and Development · China
WeGreened EB-1A approved
Washington 20 days 2026-02-09
The petition satisfied EB-1A criteria through a portfolio of 14 journal articles, 6 conference articles, and 17 preprints, which garnered citations from researchers in 42 countries. Additionally, the petitioner completed at least 60 peer reviews for field journals. The evidence demonstrated a systems-level framework for multinode architectures that provides a practical roadmap for modular quantum systems.
Assistant Professor
Engineering · China
WeGreened EB-1A approved
264 days 2026-02-06
The petition was approved based on meeting multiple EB-1A criteria, including influential authorship of 17 journal articles and 2 book chapters, and a strong citation impact of 321 citations. Additionally, the petitioner demonstrated extensive peer-review service with 110 completed reviews and provided evidence of original contributions of major significance to roadway safety and next-generation mobility.
Frequently Asked Questions
A approved EB-1A (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.
Browse More Cases
Case data sourced from publicly available petition decisions and case studies. Decision date: 2021-11-23.
Browse all casesAt a Glance
Outcome approved
Processing 11 days
Criteria Met 3 / 3
Evidence Types 6
EB-1A Case Data
Scraped Case Data
Total Cases 919
Success Rate 53.0%
Sustained 487
Dismissed 315
Related Pages
Get Case Insights
Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.
Join Waitlist